Sommadossi JP

Title : Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase - Zhou_2024_Expert.Opin.Investig.Drugs_33_9

Author(s) : Zhou XJ , Good SS , Pietropaolo K , Huang Q , Moussa A , Hammond JM , Sommadossi JP

Ref : Expert Opin Investig Drugs , 33 :9 , 2024

Abstract :

PubMedSearch : Zhou_2024_Expert.Opin.Investig.Drugs_33_9

PubMedID: 38265202

Title : AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19 - Good_2021_Antimicrob.Agents.Chemother_65_e02479

Author(s) : Good SS , Westover J , Jung KH , Zhou XJ , Moussa A , La Colla P , Collu G , Canard B , Sommadossi JP

Ref : Antimicrobial Agents & Chemotherapy , 65 :e02479 , 2021

Abstract :

PubMedSearch : Good_2021_Antimicrob.Agents.Chemother_65_e02479

PubMedID: 33558299

Sommadossi JP

References (2)

1. Bemnifosbuvir (BEM, AT-527), a novel nucleotide analogue inhibitor of the hepatitis C virus NS5B polymerase - Zhou_2024_Expert.Opin.Investig.Drugs_33_9

2. AT-527, a Double Prodrug of a Guanosine Nucleotide Analog, Is a Potent Inhibitor of SARS-CoV-2 In Vitro and a Promising Oral Antiviral for Treatment of COVID-19 - Good_2021_Antimicrob.Agents.Chemother_65_e02479